IntelliPaper
Abstract
Insulin glargine and degludec represent the second-generation basal insulins invented to fill in a clinical need for the insulin which matches the normal pattern of insulin secretion as closely as possible. Both insulins showed reduced rates of hypoglycaemia in real-world patients compared to the first-generation basal insulins. However, according to several studies, decludec demonstrated superiority in reaching optimal fasting plasma glucose targets without increasing risk of nocturnal hypoglycaemia. The aim of this study is to compare the efficacy and safety parameters of insulin degludec versus insulin degludec.
Explore Digital Article Text
Article file ID not found.
Conflict of Interest
The authors declare no conflict of interest.
Ethical Approval
Not applicable
Data Availability
The datasets used in this study are openly available at [repository link] and the source code is available on GitHub at [GitHub link].
Funding
This work did not receive any external funding.
Cite this article
Related Research
